Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has announced that its subsidiary, ReceptoPharm, has published positive results from its recent study on the use of cobratoxin for the relief of pain. ReceptoPharm is currently studying the effectiveness of Cobra Venom and Cobratoxin as treatments for Multiple Sclerosis, HIV, Adrenomyeloneuropathy (AMN), and Rabies.
"There are many historical reports of venoms being used in association with pain relief," explained Dr. Paul Reid, CEO of ReceptoPharm. "The purpose of this study was to examine the pain relieving effects of cobratoxin on laboratory mice. The results suggest that cobratoxin is effective in the relief of pain and might actually be a useful substitute for morphine," he concluded.
The study was published in the April 2006 issue of Acta Pharmacologica Sinica, an international monthly publication and the official journal of the Chinese Pharmacological Society and Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
"We are enthusiastic about the results of this recent study," commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Results like these drive ReceptoPharm's continued research and clinical studies. We hope to continue publishing positive results as we begin our phase II trials in diseases that lack treatment options, like Multiple Sclerosis and AMN," he added.
ReceptoPharm recently announced their approval by the British Medicines and Healthcare products Regulatory Agency to begin Phase II human trials for the treatment of AMN.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The publication of positive results of ReceptoPharm's pain study should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.